NewEdge Advisors LLC Grows Stake in Sanofi (NASDAQ:SNY)

NewEdge Advisors LLC increased its stake in Sanofi (NASDAQ:SNY - Free Report) by 19.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,796 shares of the company's stock after purchasing an additional 5,958 shares during the quarter. NewEdge Advisors LLC's holdings in Sanofi were worth $1,775,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of SNY. Synergy Asset Management LLC bought a new stake in shares of Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its holdings in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after acquiring an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new stake in shares of Sanofi during the fourth quarter worth $31,000. Bessemer Group Inc. boosted its holdings in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after acquiring an additional 242 shares during the period. Finally, Sierra Ocean LLC purchased a new position in shares of Sanofi in the fourth quarter valued at $44,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $63.33.

Sanofi Stock Up 1.8 %

SNY stock opened at $51.85 on Wednesday. The company's 50 day moving average is $54.61 and its 200 day moving average is $52.11. The stock has a market cap of $130.99 billion, a price-to-earnings ratio of 20.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is 64.26%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.